Cargando…

Surface-Modified Silica Hydrogels for the Programmable Release of Bisphosphonate Anti-Osteoporosis Drugs: The Case of Etidronate

Bisphosphonate drugs constitute the primary treatment for bone diseases such as Paget’s disease and osteoporosis. Despite their effectiveness, they also exhibit severe drawbacks, such as rapid excretion and limited oral bioavailability. High doses are usually administered to counterbalance these dra...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alatzoglou, Fanouria-Eirini G., Vassaki, Maria, Nirgianaki, Kalliopi, Tripodianos, Eleftherios, Turhanen, Petri, Demadis, Konstantinos D., Papathanasiou, Konstantinos E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10180253/ https://www.ncbi.nlm.nih.gov/pubmed/37176259 http://dx.doi.org/10.3390/ma16093379

Ejemplares similares

Smart, programmable and responsive injectable hydrogels for controlled release of cargo osteoporosis drugs
por: Papathanasiou, Konstantinos E., et al.
Publicado: (2017)

Drug-Inclusive Inorganic–Organic Hybrid Systems for the Controlled Release of the Osteoporosis Drug Zoledronate
por: Vassaki, Maria, et al.
Publicado: (2022)

Simple and User-Friendly Methodology for Crystal Water Determination by Quantitative Proton NMR Spectroscopy in Deuterium Oxide
por: Tynkkynen, Tuulia, et al.
Publicado: (2023)

Preparation of mixed trialkyl alkylcarbonate derivatives of etidronic acid via an unusual route
por: Turhanen, Petri A, et al.
Publicado: (2012)

Editorial: Phosphonate Chemistry in Drug Design and Development
por: Turhanen, Petri A., et al.
Publicado: (2021)

Exploiting the Multifunctionality of M(2+)/Imidazole–Etidronates for Proton Conductivity (Zn(2+)) and Electrocatalysis (Co(2+), Ni(2+)) toward the HER, OER, and ORR
por: Vílchez-Cózar, Álvaro, et al.
Publicado: (2022)

Unexpected degradation of the bisphosphonate P-C-P bridge under mild conditions
por: Turhanen, Petri A, et al.
Publicado: (2008)

Synthesis of novel (1-alkanoyloxy-4-alkanoylaminobutylidene)-1,1-bisphosphonic acid derivatives
por: Turhanen, Petri A, et al.
Publicado: (2006)

Comparison of Effect of Treatment with Etidronate and Alendronate on Lumbar Bone Mineral Density in Elderly Women with Osteoporosis
por: Iwamoto, Jun, et al.
Publicado: (2005)

Efficacy of Oral Etidronate for Skeletal Diseases in Japan
por: Iwamoto, Jun, et al.
Publicado: (2005)

Intravenous bisphosphonates for postmenopausal osteoporosis
por: Mottaghi, Peyman
Publicado: (2010)

Bisphosphonates adherence for treatment of osteoporosis
por: Vieira, Helena Parente, et al.
Publicado: (2013)

Etidronate prevents dystrophic cardiac calcification by inhibiting macrophage aggregation
por: Bauer, Carolin, et al.
Publicado: (2018)

The effect of etidronate on choroidal neovascular activity in patients with pseudoxanthoma elasticum
por: Risseeuw, Sara, et al.
Publicado: (2020)

A reappraisal of generic bisphosphonates in osteoporosis
por: Kanis, J. A., et al.
Publicado: (2011)

Bisphosphonates and glucocorticoid-induced osteoporosis: cons
por: Lems, Willem F., et al.
Publicado: (2015)

Long-term use of bisphosphonates in osteoporosis
por: Sadat-Ali, Mir, et al.
Publicado: (2017)

Long-term use of bisphosphonates in osteoporosis
por: Alwahhabi, Basmah K., et al.
Publicado: (2017)

Differences between the bisphosphonates for the prevention and treatment of osteoporosis
por: Grey, Andrew, et al.
Publicado: (2006)

Osteoporosis and Bisphosphonate-Related Osteonecrosis of the Jaw Bone
por: Villa, Alessandro, et al.
Publicado: (2011)

Patient preference in the management of postmenopausal osteoporosis with bisphosphonates
por: Reginster, Jean-Yves, et al.
Publicado: (2006)

Physicians’ perspectives on the treatment of osteoporosis patients with bisphosphonates
por: Gu, Tao, et al.
Publicado: (2016)

Novel formulations of oral bisphosphonates in the treatment of osteoporosis
por: Fuggle, Nicholas, et al.
Publicado: (2022)

ERT, HRT, Raloxifine, Calcitonin, or Bisphosphonates for Osteoporosis
por: Curtiss, Frederic R.
Publicado: (2003)

The therapeutic effect to eldecalcitol + bisphosphonate is superior to bisphosphonate alone in the treatment of osteoporosis: a meta-analysis
por: Zheng, Zaoqian, et al.
Publicado: (2020)

Seven years’ experience with etidronate in a woman with anorexia nervosa and vertebral fractures
por: Iwamoto, Jun, et al.
Publicado: (2011)

Effects of etidronate on the Enpp1(−/−) mouse model of generalized arterial calcification of infancy
por: HUESA, CARMEN, et al.
Publicado: (2015)

Chemistry of Organophosphonate Scale Growth lnhibitors: 3. Physicochemical Aspects of 2-Phosphonobutane-1,2,4-Tricarboxylate (PBTC) And Its Effect on CaCO(3) Crystal Growth
por: Demadis, Konstantinos D., et al.
Publicado: (2005)

Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis
por: Pazianas, Michael, et al.
Publicado: (2010)

Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis
por: Cotté, F.-E., et al.
Publicado: (2009)

Correction: Novel formulations of oral bisphosphonates in the treatment of osteoporosis
por: Fuggle, Nicholas, et al.
Publicado: (2023)

Bisphosphonate-based nanocomposite hydrogels for biomedical applications
por: Yuan, Weihao, et al.
Publicado: (2020)

Correction to: The therapeutic effect to eldecalcitol + bisphosphonate is superior to bisphosphonate alone in the treatment of osteoporosis: a meta-analysis
por: Zheng, Zaoqian, et al.
Publicado: (2020)

Etidronate from Medicine to Endodontics: effects of different irrigation regimes on root dentin roughness
por: TARTARI, Talita, et al.
Publicado: (2013)

Skeletal abnormalities secondary to antenatal etidronate treatment for suspected generalised arterial calcification of infancy
por: Agarwal, Neha, et al.
Publicado: (2020)

Impact of agitation/activation strategies on the antibiofilm potential of sodium hypochlorite/etidronate mixture in vitro
por: Cai, Ming, et al.
Publicado: (2022)

Influence of Ethanol on Porous Anodic Alumina Growth in Etidronic Acid Solutions at Various Temperatures
por: Kwiatkowska, Małgorzata, et al.
Publicado: (2022)

Bisphosphonates in the management of postmenopausal osteoporosis – optimizing efficacy in clinical practice
por: Bock, Oliver, et al.
Publicado: (2008)

Safety and tolerability of zoledronic acid and other bisphosphonates in osteoporosis management
por: Dalle Carbonare, Luca, et al.
Publicado: (2010)

Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk
por: Newcomb, P A, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_nk163rucgmq7ip7vampactjnnf